argenex (NASDAQ:ARGX) Given New $1,037.00 Price Target at Oppenheimer

argenex (NASDAQ:ARGX) had its price objective boosted by Oppenheimer from $1,014.00 to $1,037.00 in a research note issued to investors on Friday morning,Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

A number of other research firms have also issued reports on ARGX. Wedbush reiterated an “outperform” rating and set a $1,000.00 price objective on shares of argenex in a research note on Thursday, June 11th. Weiss Ratings raised shares of argenex from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, July 6th. Citizens Jmp lowered their target price on shares of argenex from $944.00 to $932.00 and set a “market outperform” rating on the stock in a research note on Friday. Guggenheim raised their price target on shares of argenex from $1,135.00 to $1,185.00 and gave the company a “buy” rating in a report on Friday. Finally, Glj Research upgraded shares of argenex to a “strong-buy” rating in a research report on Friday, April 3rd. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, argenex currently has an average rating of “Moderate Buy” and a consensus price target of $1,050.50.

argenex Price Performance

Shares of ARGX opened at $918.22 on Friday. argenex has a 1 year low of $587.37 and a 1 year high of $953.58. The stock’s fifty day moving average price is $868.28 and its two-hundred day moving average price is $815.12. The firm has a market cap of $57.44 billion, a PE ratio of 35.26, a PEG ratio of 1.14 and a beta of 0.45.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.86 by $1.46. The business had revenue of $1.54 billion for the quarter, compared to analysts’ expectations of $1.45 billion. argenex had a return on equity of 70.27% and a net margin of 32.19%. Sell-side analysts anticipate that argenex will post 26.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On argenex

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARGX. Assenagon Asset Management S.A. bought a new stake in shares of argenex in the 4th quarter worth approximately $20,475,000. Sivik Global Healthcare LLC bought a new stake in argenex in the fourth quarter valued at $1,261,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in argenex by 22.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,846 shares of the company’s stock valued at $9,121,000 after acquiring an additional 2,018 shares in the last quarter. M&T Bank Corp raised its holdings in argenex by 34.8% in the 4th quarter. M&T Bank Corp now owns 4,980 shares of the company’s stock worth $4,188,000 after purchasing an additional 1,286 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in argenex by 94.9% in the fourth quarter. SG Americas Securities LLC now owns 3,179 shares of the company’s stock worth $2,673,000 after buying an additional 1,548 shares during the period. 60.32% of the stock is currently owned by institutional investors.

More argenex News

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenex reported Q2 EPS of $7.32, topping estimates, on revenue of $1.54 billion versus expectations of $1.45 billion, highlighting strong operating momentum and profitability. Q2 earnings report and conference call
• Positive Sentiment: Reuters reported that global sales of Vyvgart jumped in the second quarter, a key driver for argenex’s growth and a major reason the stock has been gaining investor attention. Reuters article on Vyvgart sales
• Positive Sentiment: Oppenheimer, RBC, and Guggenheim all raised price targets and maintained bullish ratings, signaling increased Street confidence in argenex’s growth trajectory and pipeline prospects.
• Positive Sentiment: A Seeking Alpha note highlighted surging profitability, robust cash generation, and operational leverage, while pointing to pipeline catalysts such as empasiprubart as additional upside potential. Seeking Alpha rating upgrade article
• Neutral Sentiment: Short-interest data showed 0 shares reported, which provides little actionable signal for investors because the figures appear unchanged and unusually low.
• Negative Sentiment: Citizens JMP trimmed its price target slightly from $944 to $932, though it still kept a positive rating, making this more of a minor caution than a bearish call.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.